# Ani Pharmaceuticals Inc. (ANIP)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.73B  
**Price:** $81.46 (-0.48%)

> ANI Pharmaceuticals Inc. is a diversified biopharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceuticals. It specializes in a range of dosage forms, including liquid, powder, oral solid-dose products, injectables, softgel capsules, semi-solids, topicals, and controlled substances. The company operates through key segments: Rare Disease, featuring novel therapeutics in ophthalmology, rheumatology, nephrology, neurology, and pulmonology, such as Purified Cortrophin Gel, ILUVIEN, and YUTIQ; Generics, leveraging R&D expertise and U.S.-based manufacturing for products like Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone, and Vancomycin; and Established Brands. ANI Pharmaceuticals Inc. focuses on areas like narcotics, oncolytics, hormones, steroids, and complex formulations including extended-release and combination products. Primarily serving the United States and Canada, it emphasizes high-quality therapeutics through operational excellence and North American manufacturing capabilities. Founded in 2001 and headquartered in Baudette, Minnesota, ANI Pharmaceuticals Inc. plays a vital role in addressing patient needs across specialized pharmaceutical markets.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $883M | — | $111M | $78M | — |
| 2024 | $614M | — | $584,000 | -$19M | — |
| 2023 | $487M | — | $47M | $19M | — |
| 2022 | $316M | — | -$35M | -$48M | — |
| 2021 | $216M | — | -$40M | -$43M | — |
| 2020 | $208M | $121M | -$16M | -$23M | — |
| 2019 | $207M | $143M | $16M | $6M | — |
| 2018 | $202M | $129M | $35M | $15M | — |
| 2017 | $177M | $98M | $28M | -$1M | — |
| 2016 | $129M | $80M | $20M | $4M | — |
| 2015 | $76M | $64M | $33M | $15M | — |
| 2014 | $56M | $44M | $20M | $29M | — |
| 2013 | $30M | $20M | $898,000 | $301,000 | — |
| 2012 | $20M | $11M | -$42,000 | -$2M | — |
| 2011 | $435,160 | — | — | — | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.44B | $900M | $541M | $286M | $292M |
| 2024 | $1.28B | $856M | $404M | $145M | $309M |
| 2023 | $904M | $447M | $433M | $221M | $285M |
| 2022 | $760M | $422M | $314M | $48M | $286M |
| 2021 | $772M | $413M | $334M | $100M | $287M |
| 2020 | $461M | $265M | $196M | $8M | $172M |
| 2019 | $457M | $244M | $213M | $62M | $176M |
| 2018 | $431M | $233M | $197M | $43M | $67M |
| 2017 | $412M | $237M | $175M | $31M | $128M |
| 2016 | $323M | $153M | $170M | $27M | $121M |
| 2015 | $285M | $125M | $160M | $155M | $113M |
| 2014 | $260M | $120M | $140M | $169M | $107M |
| 2013 | $45M | $4M | $41M | $11M | — |
| 2012 | $14M | $11M | -$43M | $11,000 | — |
| 2011 | $62M | $25M | -$34M | — | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $185M | $14M | $171M |
| 2024 | $64M | $16M | $48M |
| 2023 | $119M | $9M | $110M |
| 2022 | -$31M | $9M | -$40M |
| 2021 | $3M | $3M | $765,000 |
| 2020 | $15M | $6M | $9M |
| 2019 | $46M | $7M | $39M |
| 2018 | $67M | $6M | $61M |
| 2017 | $39M | $10M | $29M |
| 2016 | $27M | $5M | $23M |
| 2015 | $17M | $2M | $15M |
| 2014 | $22M | $1M | $21M |
| 2013 | -$5M | $191,000 | -$6M |
| 2012 | -$137,000 | $292,000 | -$429,000 |

Source: [CompaniesByCap](https://companiesbycap.com/company/ANIP)